

Milind Javle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1992104/publications.pdf>

Version: 2024-02-01

88
papers

5,854
citations

76196

40
h-index

79541

73
g-index

90
all docs

90
docs citations

90
times ranked

7834
citing authors

#	ARTICLE	IF	CITATIONS
1	The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. <i>Hepatology</i> , 2022, 75, 297-308.	3.6	32
2	Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma. <i>American Journal of Transplantation</i> , 2022, 22, 823-832.	2.6	41
3	Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinoma. <i>Surgical Oncology</i> , 2022, 40, 101696.	0.8	1
4	Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, 5, 26-30.	0.6	1
5	Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH1-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. <i>JCO Precision Oncology</i> , 2022, 6, e2100197.	1.5	10
6	Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2022, 28, 2229-2236.	3.2	13
7	Evaluation and Management of Liver Transplant Candidates With Prior Nonhepatic Cancer: Guidelines From the ILTS/SETH Consensus Conference. <i>Transplantation</i> , 2022, 106, e3-e11.	0.5	2
8	Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 1901.	1.7	15
9	Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. <i>Cancer</i> , 2022, 128, 2529-2539.	2.0	7
10	Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. <i>Cancer Discovery</i> , 2022, 12, 2330-2349.	7.7	22
11	Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. <i>Annals of Surgery</i> , 2021, 273, 806-813.	2.1	61
12	Time to Rethink Upfront Surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant Experience. <i>Annals of Surgical Oncology</i> , 2021, 28, 6725-6735.	0.7	23
13	Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants. <i>JAMA Oncology</i> , 2021, 7, 693.	3.4	56
14	Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 45-52.	0.6	5
15	FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. <i>Cancers</i> , 2021, 13, 2968.	1.7	63
16	FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma. <i>Current Oncology Reports</i> , 2021, 23, 108.	1.8	23
17	Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial. <i>Journal of Pain and Symptom Management</i> , 2021, 62, 223-232.e1.	0.6	2
18	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2021, 22, 1290-1300.	5.1	178

#	ARTICLE	IF	CITATIONS
19	Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 803-815.	3.7	205
20	Adopting Consensus Terms for Testing in Precision Medicine. <i>JCO Precision Oncology</i> , 2021, 5, 1563-1567.	1.5	7
21	Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 1270.	1.1	3
22	Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2020, 271, 996-1002.	2.1	34
23	Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. <i>Nature Communications</i> , 2020, 11, 5332.	5.8	15
24	Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2020, 155, 832.	2.2	105
25	Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. <i>Lancet Oncology</i> , The, 2020, 21, 1234-1243.	5.1	297
26	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1924-1931.	3.2	50
27	Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trial. <i>Future Oncology</i> , 2020, 16, 2375-2384.	1.1	62
28	Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. <i>Investigational New Drugs</i> , 2020, 38, 1763-1773.	1.2	3
29	On the cusp of a sea change in biliary tract cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 1-1.	0.4	1
30	Interventional radiology approaches for intra-hepatic cholangiocarcinoma. <i>Chinese Clinical Oncology</i> , 2020, 9, 8-8.	0.4	13
31	Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. , 2020, 8, e000587.		62
32	Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. <i>Scientific Reports</i> , 2020, 10, 22087.	1.6	21
33	Liver Transplantation for Cholangiocarcinoma and Mixed Hepatocellular Cholangiocarcinoma: Working Group Report From the ILTS Transplant Oncology Consensus Conference. <i>Transplantation</i> , 2020, 104, 1125-1130.	0.5	56
34	Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 604-614.	0.7	34
35	Preoperative drainage for perihilar cholangiocarcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 10-11.	3.7	1
36	Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. <i>Gastroenterology</i> , 2019, 156, 108-118.e4.	0.6	270

#	ARTICLE	IF	CITATIONS
37	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF mutated melanoma and other advanced malignancies. <i>Cancer</i> , 2019, 125, 463-472.	2.0	10
38	First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 619-627.	0.7	8
39	Systemic therapy for gallbladder cancer. <i>Chinese Clinical Oncology</i> , 2019, 8, 44-44.	0.4	27
40	Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1595-1601.	1.9	30
41	Portomesenteric Venous Stenting for Palliation of Ascites and Variceal Bleeding Caused by Prehepatic Portal Hypertension. <i>Oncologist</i> , 2018, 23, 712-718.	1.9	9
42	Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 337-348.	3.7	189
43	Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. <i>Cancer Cell</i> , 2018, 33, 752-769.e8.	7.7	58
44	Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical Phenotype. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	86
45	Phase II Study of BGJ398 in Patients With <i>FGFR</i> -Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	0.8	524
46	Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 300.	1.8	78
47	A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. <i>Cancer</i> , 2018, 124, 3890-3899.	2.0	5
48	Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. <i>Cancer Medicine</i> , 2018, 7, 4880-4892.	1.3	23
49	Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 71.	6.9	30
50	Liver transplantation for locally advanced intrahepatic cholangiocarcinoma – Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 529-530.	3.7	5
51	A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5883-5894.	3.2	76
52	A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. <i>British Journal of Cancer</i> , 2017, 116, 575-583.	2.9	73
53	Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. <i>British Journal of Cancer</i> , 2017, 116, 697-702.	2.9	70
54	Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1791-1799.	2.4	76

#	ARTICLE	IF	CITATIONS
55	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5648-5656.	3.2	50
56	Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients. <i>Cancer</i> , 2017, 123, 1354-1362.	2.0	37
57	4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7263-7275.	3.2	41
58	Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma. <i>Cancer Control</i> , 2017, 24, 107327481772924.	0.7	79
59	Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2017, 152, 1048.	2.2	82
60	Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. <i>Annals of Surgical Oncology</i> , 2017, 24, 2031-2039.	0.7	30
61	Single-cell mRNA profiling reveals transcriptional heterogeneity among pancreatic circulating tumour cells. <i>BMC Cancer</i> , 2017, 17, 390.	1.1	36
62	Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. <i>Cancer</i> , 2017, 123, 1011-1017.	2.0	45
63	Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 164-174.	0.9	124
64	Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments?. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 105-116.	0.7	26
65	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. <i>Oncotarget</i> , 2017, 8, 87163-87173.	0.8	0
66	RNA sequencing-based analysis of gallbladder cancer reveals the importance of the liver X receptor and lipid metabolism in gallbladder cancer. <i>Oncotarget</i> , 2016, 7, 35302-35312.	0.8	16
67	Molecular profiling of biliary tract cancer: a target rich disease. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 797-803.	0.6	79
68	Mutational Profiles Reveal an Aberrant TGF- β 2-CEA Regulated Pathway in Colon Adenomas. <i>PLoS ONE</i> , 2016, 11, e0153933.	1.1	17
69	Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2016, 122, 2671-2679.	2.0	49
70	Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. <i>Current Treatment Options in Oncology</i> , 2016, 17, 58.	1.3	88
71	Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. <i>Cancer</i> , 2016, 122, 3657-3666.	2.0	41
72	Laparoscopic Management of Gallbladder Cancer: A Stepwise Approach. <i>Annals of Surgical Oncology</i> , 2016, 23, 892-893.	0.7	12

#	ARTICLE	IF	CITATIONS
73	Biliary cancer: Utility of next-generation sequencing for clinical management. <i>Cancer</i> , 2016, 122, 3838-3847.	2.0	289
74	Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1975-1985.	0.9	42
75	The inflammatory inception of gallbladder cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 245-254.	3.3	71
76	Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. <i>Journal of Clinical Pathology</i> , 2016, 69, 403-408.	1.0	56
77	The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. <i>Annals of Surgical Oncology</i> , 2015, 22, 1221-1228.	0.7	44
78	HER2/neu-directed therapy for biliary tract cancer. <i>Journal of Hematology and Oncology</i> , 2015, 8, 58.	6.9	191
79	Gallbladder Cancer: expert consensus statement. <i>Hpb</i> , 2015, 17, 681-690.	0.1	334
80	Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 489-498.	1.1	59
81	LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy. <i>Oncotarget</i> , 2015, 6, 10940-10949.	0.8	31
82	Ramucirumab: Successfully Targeting Angiogenesis in Gastric Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5875-5881.	3.2	82
83	The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma. <i>Nature Medicine</i> , 2014, 20, 596-598.	15.2	111
84	Biomarkers of TGF- β 2 Signaling Pathway and Prognosis of Pancreatic Cancer. <i>PLoS ONE</i> , 2014, 9, e85942.	1.1	99
85	Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications. <i>PLoS ONE</i> , 2014, 9, e115383.	1.1	362
86	Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma. <i>Practical Radiation Oncology</i> , 2013, 3, 344-348.	1.1	4
87	Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma. <i>Hepatic Medicine: Evidence and Research</i> , 2010, 2, 147.	0.9	3
88	Pilot Study of Gefitinib, Oxaliplatin, and Radiotherapy for Esophageal Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 329-334.	0.6	32